Index

Accuhaler, 81, 82, 83
Acetylcholine, 16, 18, 63
Acinus, 12
Action plans, 103–7, 116, 161–2
Activity scores, 160
Acupuncture, 150
Acute exacerbations, 134, 136–41
ADAM33 gene, 170
Add-on therapy, 93–4, 95–7
Administration routes, 71
Adrenaline, 16, 17, 43, 60–1
Adrenal suppression, 58
Aetiology, 22–4, 169–71
Air pollution, 101, 120–2, 170
Airway structure, 7–9
Airway wall remodelling, 27–8
Allergens
  avoidance, 99–101, 113
  desensitization, 145–6
  triggers, 23, 25
Allergic bronchopulmonary aspergillosis, 53
Allergies, 34
Allergy tests, 102
Alpha-1 antitrypsin, 50, 135, 146
Alveoli, 12, 13, 19
Aminophylline, 65, 139
Amy’s story, 43, 45, 92, 133
Antibiotics, 139
Anticholinergics
  deteriorating asthma, 138–9
  dry powder devices, 74, 82
  pharmacology, 63–4
Anti-immunoglobulin E, 146, 172
Antimuscarinic bronchodilators, see
Anticholinergics
Apex of lung, 11, 13
Aspergillosis, 53
Aspiration pneumonia, 52–3
Aspirin, 23
Assessment process, 33–44, 134
see also Diagnosis
Association of Respiratory Technicians and
Physiologists, 38
Asthma Action Plans, 103–7, 116, 161–2
Asthma registers, 156–7
Audits, 162–3
Autohaler, 76, 77
Autonomic nervous system, 16–18, 60–1, 63–4,
  150
Autonomy of nurses, 173–4
B2 agonists, 4–5, 60–3, 74, 82, 138
B2 receptors, 16, 17, 23
Basement membrane, 7, 8
Beclometasone, 56, 74, 76, 77, 81, 82
Beta blockers, 23
Bill’s story, 43, 45
Breastfeeding, 99, 110
Breath-activated metered dose inhalers, 76
Breath holding, 80
Breathing exercises, 151
Breathing mechanism, 15–16
Breathlessness, 32–3
British Thoracic Society (BTS)
  definition of asthma, 24
  drug therapy, 55
  family therapy, 152
  guidelines, 38, 46, 90–1, 94, 98, 169
  mortality study, 3
  poor control, 94
  spirometry, 38
  stepwise management, 131
Brittle asthma, 122–3
Bronchi
  anatomy/physiology, 8, 10–11, 13
  hyperreactivity, 26–7
  smooth muscle, 7–8, 16–19, 26–7
  thermoplasty, 172
Bronchiectasis, 50
Bronchioles, 12, 13, 171
Bronchodilators, 60–7
  mortality, 4
  reversibility test, 42
  short-acting, 61, 68, 74, 82
  stepwise management, 93–7
  subcutaneous, 146–7
Bronchopulmonary aspergillosis, 53
BTS, see British Thoracic Society
Budesonide, 56, 68
Buteyko breathing method, 151
Candidiasis, oral, 58
Carbon dioxide, 18, 20
Cardiac failure, 49
Care structure, 155–66
Cartilage, airways, 8, 9, 10–11
Case studies
Amy, 43, 45, 92, 133
Bill, 43, 45
Emily, 135
Gary, 37
Causation, 22–4, 169–71
Cells, respiratory system, 7–10
CFCs, see Chlorofluorocarbons
Children
action plans, 104–7
Amy’s story, 43, 45, 92, 133
management, 110–15
objective measurements, 136–7
prevalence studies, 1–3
schools 165–6
stepwise management, 96, 97
symptom diaries, 47
under five, 44–7, 64, 97, 112–13
Chlorofluorocarbons (CFCs), 74, 76–8
Choices of therapy, 57–8, 71–3, 94–7
Chronic obstructive pulmonary disease (COPD)
Bill’s story, 43, 45
differential diagnosis, 49–50
elderly patients, 117
Handihaler, 84
respiratory centre, 20
spirometry, 39
Chronic severe asthma, 129–53
Ciclesonide, 56, 96
Cigarette smoking, 23, 99, 101, 110, 125,
164
Ciliated epithelium, 7, 8, 9, 10
Cleanliness, 23, 73, 79, 171
Clinical features of asthma, 31–3
Clinical governance, 142
Clinics, 157–8
‘Cold freon effect’, 74
Columnar epithelium, 7, 8, 10
Combined therapies, 68, 74, 82
Commission on Human Medicines, 5
Common cold, 23, 104
Competence, professional, 173–4
Complementary therapies, 148–52
Compressors, 86, 87
Concordance with treatment, 125–6, 132, 159,
163–4
Congestive cardiac failure, 49
Continuous oral steroid use, 94, 95–7
Control
clinic questions, 159
Jones Morbidity Index, 161
respiration, 16–19
symptoms, 90
Tayside Stamp, 159, 160
COPD, see Chronic obstructive pulmonary disease
Cor pulmonale, 18
Corticosteroids, 55–60
see also individual drugs; Inhaled steroids; Oral
steroids
Costs, 1, 5, 72
Cough, 32, 110, 111
Cromones, 67
Cuboidal epithelium, 7
Cyclosporin, 147–8
Cysteinyl-leukotrienes, 66
Cystic fibrosis, 51
Cytokines, 25, 26, 27, 172
Daytime Tayside score, 160
Deaths, 1, 3–5, 62–3
Definition of asthma, 24
Depression, 124
Desensitization, 145–6
Deteriorating asthma, 129–53
Devices, see Inhaler devices; Nebulizers
Diagnosis, 31–53
allergic bronchopulmonary aspergillosis, 53
alpha-1 antitrypsin deficiency, 50
bronchiectasis, 50
children, 110–11
congestive cardiac failure, 49
COPD, 49–50
cystic fibrosis, 51
differential, 47–8, 117, 134
flow chart, 46
gastro-oesophageal reflux, 48–9
interstitial lung disease, 51–2
occupational asthma, 121–2
prevalence study criteria, 2
pulmonary emboli, 52
tests, 35–44
vocal cord dysfunction, 53
Diaphragm, 11, 14
Diaries, 47, 48, 104, 122
Diet, 101–2, 114, 152
Differential diagnosis, 47–8, 117, 134
INDEX

'Difficult-to-manage' situations, 109–26
Diffusion, pulmonary, 18, 19–20
Discharge from hospital, 140–1
Disease characteristics, 21–8, 39–40
Diskhaler, 81, 82, 83
District nurses, 163
Dosage, 57, 97–8
Drug therapy, 55–69
  see also individual drugs
    acute attacks, 138–9
    anticholinergics, 63–4, 74, 82, 138–9
    B2 agonists, 4–5, 23, 60–3, 74, 82, 138
    children, 111–13
    combinations, 68, 74, 82
    corticosteroids, 55–60
    cromones, 67
    deteriorating asthma, 133
    elderly patients, 117
    inhaler devices, 71–88
    leukotriene receptor antagonists, 66–7
    metered dose inhalers, 74–6, 78–9, 81
    methylxanthines, 65–6, 93–4, 120
    pregnancy, 120
    stepwise management, 91–8
Dry powder inhaler devices, 79, 81–5
Early life experiences, 99, 110, 170–1
Early response, 25, 27
Easi-breathe device, 76, 77
Economic aspects, 1, 5, 72
ECRHS, see European Community Respiratory Health Survey
Education
  nurses, 174
  patients, 73–80, 83–5, 98, 103–4, 113
Elasticity, lung, 13
Elderly patients, 72, 78, 117–18, 164–5
Emily’s story, 135
Environment, 101, 120–2, 170
Epidemiology, 1–5
Epiglottis, 10, 11
Epithelial airway cells, 7–10
European Community Respiratory Health Survey (ECRHS), 2
Evidence-based indicators, 157, 158
Exercise, 114–15
Exercise test, 43–4
Expiration, 15–16, 35–42
Family history, 22, 34
Family therapy, 151–2
Fenoterol, 4, 62
FEV1, see Forced expiratory volume in one second
Fibrosis, airway wall, 27–8
Flow chart, diagnosis, 46
Flow volume graphs, 40
Fluticasone, 56, 68, 74, 81, 82, 95
Follow-up, acute attacks, 141
Foods, 24, 101–2, 114, 152
Forced expiratory volume in one second (FEV1), 41
Forced inspiration/expiration, 15–16
Forced vital capacity (FVC), 41
Foreign bodies, 52–3
Formoterol, 68
Frequent oral steroid use, 94
Future trends, 169–72
FVC, see Forced vital capacity
Gary’s story, 37
Gas exchange, 12, 13, 19–20
Gastro-oesophageal reflux, 48–9
Gender differences, 118
General Medical Services Contract for General Practitioners, 2, 157
General practice, 2, 156–63
Genetics, 22, 169–70
GINA, see Global Initiative for Asthma
Ginkgo biloba, 149, 150
Global Initiative for Asthma (GINA), 90–1, 98
Goal-setting, 91
Goblet cells, 8, 9, 11
Gold, 148
GP practices, 2, 156–63
Growth retardation, 58, 60
Guidelines
  BTS, 90–1, 94, 98, 169
  GINA, 90–1, 98
  life-threatening asthma, 137
  management, 90–8
  MHRA for add-on therapy, 93
NICE, 112–13
Guidelines for the Measurement of Respiratory Function, 37–8
Haleraid, 75
Handihaler, 82, 84, 85
Healthcare structure, 155–66
Health visitors, 164
Heart, 19, 49
Herbal medicines, 149–50
History of asthma, 21–2
History-taking, 33–4
INDEX

Homeopathy, 150
Homes, cleanliness, 23, 100, 113, 23, 171
Home visits, 163–4
Hospitals, 137, 139–41
House dust mite, 100, 113
‘Hygiene hypothesis’, 23, 171
Hyperreactivity, 26–7
Hyperventilation, 51
Hypnosis, 151

Immunoglobulin E (IgE)
allergen response, 25–7
allergy tests, 102
anti-IgE therapy, 146, 172

Immunology, 171–2
Immunosuppressant therapy, 147
Immunotherapy, 102–3, 145–6, 171–2
Incidence, 1–2
Indicators, 2, 157, 158
Inflammatory response, 25–7, 56
Influenza vaccine, 148

Inhaled B2 agonists, 4–5, 61–3, 74, 82, 138
Inhaled bronchodilators, 4, 42, 60–7, 93–7
Inhaled steroids
see also Oral steroids
children, 112–13
choice, 94–7
dose, 98
dry powder devices, 74, 82
frequent use, 94
pharmacology, 56–9
regular, 92–3, 95–7
stepwise management, 92–8
symptom diary, 48
Inhaler devices, 71–88
breath-actuated metered dose inhalers, 76
children, 112–13, 114–15
choice, 71–3
dry powder, 79, 81–5
elderly patients, 118
schools, 165
spacer devices, 78–9, 81
techniques, 73–5, 77, 79, 80, 83–5
Inspiration mechanism, 15–16
Inspiratory capacity, 72
Inspiratory flow meters, 72
Intensive care, 140
Interferon, 171
Interleukins, 172
International prevalence studies, 2

International Study of Asthma and Allergies in
Childhood (ISAAC), 2
Interstitial lung disease, 51–2
Ipratropium, 63, 64, 68, 85

Jones Morbidity Index, 159, 161

LABA, see long-acting B2 agonists

Lamina propria, 7, 10, 11
Large volume spacers, 80
Larynx, 9–10, 11
Late response, 25, 27
Length of action, 57, 64
Leukotriene receptor antagonists, 66–7, 93, 95–7
Life-threatening asthma, 137–41
Ligusticum wallichii, 149
Lobes of lung, 13
Long-acting B2 agonists (LABA), 4–5, 62, 93, 95–7
Lower respiratory tract, 10–13

Lungs
anatomy, 13
circulation, 18–19
deposition, 76
diffusion, 19–20
dermatol, 52
function, 35, 39–43
perfusion, 18
tumours, 51

Magnesium sulphate, 139

Management
brittle asthma, 123
children, 110–15
deteriorating asthma, 131–42
elderly patients, 117–18
menstrual asthma, 118–20
nonpharmacological, 98–104
occupational asthma, 122
pharmacological, 91–8
prophylactic, 99–107
special situations, 109–26
structure of care, 155–66
teenagers, 116

Managing Medicines in Schools and Early Years
Settings, 166

Mast cell degranulation, 27
MDIs, see Metered dose inhalers
Mediastinum, 14
Medication, see Drug therapy
INDEX

Medicines and Healthcare products Regulation Agency (MHRA), 93
Menstrual asthma, 118–20
Metabolic control, 18
Metered dose inhalers (MDIs), 74–6, 78–9, 81
Methotrexate, 147
Methylxanthines, 65–6
MHRA, see Medicines and Healthcare products Regulation Agency
Mild intermittent asthma, 91, 95–7
Mometasone furoate, 56
Monitoring, 115, 130
Montreal Protocol, 76
Mortality, 1, 3–5, 62–3
Mucociliary system, 9
Mucus, 8, 9, 33
Muscles of respiration, 11, 14–16
National Health Service, 5
National Institute for Clinical Excellence (NICE), 112–13
Nebulizers, 84–7
Nervous control of respiration, 16–19
Newsgiving, 91
New Zealand, Tokelau refugees, 22–3
NICE, see National Institute for Clinical Excellence
Nighttime Tayside score, 160
Nonpharmacological management, 98–104, 113–15
Nor-adrenaline, 17
Normal lung function, 39–40, 41
Nose, 9, 11
Nurse consultants, 174
Nursing homes, 164–5
Nursing and Midwifery Council Code of Conduct, 173–4
Nursing staff, 162–6, 173–4
Objective measurements, 35, 39–41, 136–7, 159
Obstructive lung disease, 39–40, 41
Occupational asthma, 120–2
Oral methylxanthines, 65–6
Oral steroids see also Inhaled steroids
acute attacks, 138
frequent use, 94, 95–7
mode of action 56
pharmacology, 59–60
starting, 98
Outcome measures, 162–3
Oxygen cylinders, 87
Oxygen saturation, 19–20, 136–7, 138, 140
Parasympathetic nervous system, 16–17, 18, 60–1, 63–4
Particle size, 72
Patients assessment, 33–44, 134
difficulties, 39, 72, 91
education, 73–80, 83–5, 98, 103–4, 113
registers, 156–7
Peak expiratory flow rate (PEFR), 35, 136
Peak flow diaries, 122
meters, 35–6
monitoring, 42, 43, 122, 130
PEFR, see Peak expiratory flow rate
‘Perfect’ control, 90
Persistent poor control, 94, 95–7
Pets, 100–1, 114
Pharmacological therapy, see Drug therapy
Pharynx, 9
Physical examinations, 34
Pituitary gland, 58
Placebo devices, 73
Pleura, 14
Pneumocytes, type I/II, 12
Pneumonia, 52–3
Portable spirometers, 38
Practice nurses, 62
Pregnancy, 99, 110, 120
Preschool children, 44–7, 64, 97, 112–13
Presentation, 31–53
Prevalence, 1, 2, 3, 22–3, 123
Preventer therapy, 55, 92–3, 95–7, 132, 133
see also Corticosteroids; Inhaled steroids
Primary healthcare, 156–66, 173–4
Primary prophylaxis, 99
Professional competence, 173–4
Propellants, 76–8
Prophylactic management, 99–107, 132, 133
Protocols, 156, 162, 165
Psychological aspects, 123–4
asthma, 22
asthma deaths, 3
deteriorating asthma, 131
teenagers, 116
triggers, 24
Pulmonary, see Lungs
Pulse, 136–7
Quality and Outcomes Framework (QOF), 2, 3, 156, 157, 158
Quiet inspiration/expiration, 15

Radioallergosorbent test (RAST), 102
Record-keeping, 161, 156–7
Referral to specialists, 49, 111
Registers, 156–7
Regular preventative therapy, 92–3, 95, 96, 97
Relaxation, 150–1
Relievers of asthma, 55
see also Bronchodilators
Residential homes, 164–5
Respiration rate, 136–7
Respiration types, 7
Respiratory centre, 16, 20
Respiratory syncytial virus (RSV), 171
Respiratory system, 7–20
breathing mechanism, 15–16
control, 16–19
definition, 7
lower respiratory tract, 10–13
muscles, 14–16
upper respiratory tract, 9–10
Responsibilities, see Roles
Restrictive lung disease, 39–40, 41
Reversibility test, 42
Review process, 115, 141, 157–62
Rhinovirus (RV), 171
Risk factors, 110, 123, 131
Risk-taking behaviour, 116
Roles
district nurses, 163
health visitors, 164
nurses, 173–4
practice nurses, 162
school nurses, 166
Royal College of Physicians’ ‘three questions’, 159
RSV, see Respiratory syncytial virus
RV, see Rhinovirus

Salbutamol, 61, 68, 74, 82, 85
School nurses, 166
Schools, 165–6
Scoring systems, 159–61
Secondary prophylaxis, 99–104
Sedatives, 139
Self-management, 103–4, 133–4
Self-reported wheeze, 2
Service indicators, 2, 3, 156, 157, 158

Severe chronic asthma, 129–53
Short-acting bronchodilators, 61, 68, 74, 82
Short-acting inhaled B2 agonists, 61
Side effects
anticholinergics, 64
cromones, 67
inhaled B2 agonists, 62–3
inhaled steroids, 58–9
leukotriene receptor antagonists, 67
methylxanthines, 65–6
oral corticosteroids, 59–60
‘Silent chest’, 137
Slow vital capacity (SVC), 41
Small volume spacers, 78–9, 81, 118
Smoking, 23, 99, 101, 110, 125, 164
Smooth muscle, bronchial, 7–8, 16–19, 26, 27
Social aspects, 5
Sodium cromoglycate, 84, 112
Spacer devices, 78–9, 80
Specialist referral, 49, 111
Special situations, 109–26
Spinhaler, 82, 84, 85
Spirometer, 41–2
Spirometry, 37–42
Standardized mortality ratio, 4
Stepwise management, 91–8, 131
Steroid reversibility test, 42
Steroids, see Corticosteroids; Inhaled steroids;
Oral steroids
Stress, 24
Structure of care, 155–66
Structured reviews, 157–62
Subcutaneous bronchodilators, 146–7
SVC, see Slow vital capacity
Sympathetic nervous system, 16, 17, 60–1, 63–4
Symptoms
control, 90, 159, 160, 161
deteriorating asthma, 130
diaries, 47, 48, 104
history-taking, 33–4
Synacthen test, 58
Tayside Stamp, 159–60
Techniques
Accuhaler, 83
Autohaler, 77
children’s inhalers, 113
Diskhaler, 83
easi-breathe device, 77
Handihaler, 85

INDEX
INDEX

metered dose inhalers, 74–5
spacer devices, 79, 80
Spinhaler, 85
stepwise management checks, 98
teaching, 73
Turbohaler, 84
Teenagers, 116, 135
Terbutaline, 61
Tetracosactrin, 58
Theophylline, 65, 93–4, 120
Thorax, 14
Tidal breathing, 80
tight chest, 32
Tiotropium, 84
Tokelau, New Zealand, 22–3
Trachea, 10, 11, 13
Training courses, 174
Treatment concordance, 125–6, 132, 159, 163–4
Triggers, 22–7, 121, 132

Complied by Indexing Specialists (UK)